Bharat Biotech Covaxin finds place in Oman list of approved COVID vaccines

Published On 2021-10-29 10:16 GMT   |   Update On 2021-10-29 10:16 GMT

New Delhi: Bharat Biotech's Covaxin has been included to the approved list of COVID-19 vaccines for travel to Oman without quarantine.

In a tweet, Bharat Biotech noted: "Covaxin has now been added to the approved list of #COVID19 vaccines for travel to Oman without quarantine. This will facilitate travelers from India vaccinated with Covaxin."
The vaccine major cited a press release issued by the Embassy of India, Muscat, in this regard.
"Embassy of India, Muscat, is pleased to inform that the Government of the Sultanate of Oman has added Covaxin to the approved list of COVID-19 vaccines for travel to Oman. The Civil Aviation Authority issued a notification on 27 October regarding this," the release stated.
All passengers from India who have received two doses of Covaxin at-least 14 days before the estimated arrival date will now be able to travel to Oman without the requirement of quarantine, it added.
Advertisement
All other COVID-19 related requirements/conditions, such as pre-arrival RT-PCR test shall be applicable for such passengers, the release stated.
This notification will significantly ease travel to Oman for Indian nationals who have taken Covaxin, it noted.
Passengers who have taken AstraZeneca/Covishield are already permitted to travel to Oman without quarantine.





Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News